# Enanta Pharmaceuticals Inc: overview ENTA · Nasdaq · CIK 1177648 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Sep 30 Pages: [Overview](/companies/enta.md) · [Financials](/companies/enta/financials.md) · [Filings](/companies/enta/filings.md) · [Insiders](/companies/enta/insiders.md) Latest reported revenue: [$14.4m](/filings/0001193125-26-345719.md) for Q3 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 12, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-345719). ## Last eight quarters | Line item | Unit | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [14.6 d](/filings/0001193125-25-288121.md) | [17.0](/filings/0001193125-26-046502.md) | [14.9](/filings/0001193125-26-220572.md) | [18.3](/filings/0001193125-26-345719.md) | [15.1 d](/filings/0001193125-25-288121.md) | [18.6](/filings/0001193125-26-046502.md) | [17.2](/filings/0001193125-26-220572.md) | [14.4](/filings/0001193125-26-345719.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(204.4%) d](/filings/0001193125-25-288121.md) | [(138.8%)](/filings/0001193125-26-046502.md) | [(164.3%)](/filings/0001193125-26-220572.md) | [(103.2%)](/filings/0001193125-26-345719.md) | [(121.6%) d](/filings/0001193125-25-288121.md) | [(60.5%)](/filings/0001193125-26-046502.md) | [(69.1%)](/filings/0001193125-26-220572.md) | [(120.0%)](/filings/0001193125-26-345719.md) | | Net margin | % | [(197.3%) d](/filings/0001193125-25-288121.md) | [(131.4%)](/filings/0001193125-26-345719.md) | [(151.7%)](/filings/0001193125-26-345719.md) | [(99.7%)](/filings/0001193125-26-345719.md) | [(123.6%) d](/filings/0001193125-26-345719.md) | [(64.1%)](/filings/0001193125-26-345719.md) | [(76.3%)](/filings/0001193125-26-345719.md) | [(135.8%)](/filings/0001193125-26-345719.md) | | Diluted EPS | $ per share | not reported | [(1.05)](/filings/0001193125-26-046502.md) | [(1.06)](/filings/0001193125-26-220572.md) | [(0.85)](/filings/0001193125-26-345719.md) | not reported | [(0.42)](/filings/0001193125-26-046502.md) | [(0.45)](/filings/0001193125-26-220572.md) | [(0.67)](/filings/0001193125-26-345719.md) | | Free cash flow | $m | [(19.4) d](/filings/0001193125-25-288121.md) | [(25.5)](/filings/0001193125-26-046502.md) | [(16.0) d](/filings/0001193125-26-220572.md) | [17.4 d](/filings/0001193125-26-345719.md) | [(7.9) d](/filings/0001193125-25-288121.md) | [(11.8)](/filings/0001193125-26-046502.md) | [(7.2) d](/filings/0001193125-26-220572.md) | [(10.0) d](/filings/0001193125-26-345719.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-09-30) | FY2022 (2022-09-30) | FY2023 (2023-09-30) | FY2024 (2024-09-30) | FY2025 (2025-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [97.1](/filings/0000950170-23-065884.md) | [86.2](/filings/0000950170-24-131260.md) | [79.2](/filings/0001193125-25-288121.md) | [67.6](/filings/0001193125-25-288121.md) | [65.3](/filings/0001193125-25-288121.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(112.9%)](/filings/0000950170-23-065884.md) | [(143.7%)](/filings/0000950170-24-131260.md) | [(173.2%)](/filings/0001193125-25-288121.md) | [(179.9%)](/filings/0001193125-25-288121.md) | [(130.7%)](/filings/0001193125-25-288121.md) | | Net margin | % | [(81.4%)](/filings/0000950170-23-065884.md) | [(141.3%)](/filings/0000950170-24-131260.md) | [(169.0%)](/filings/0001193125-25-288121.md) | [(171.6%)](/filings/0001193125-25-288121.md) | [(125.4%)](/filings/0001193125-26-345719.md) | | Diluted EPS | $ per share | [(3.92)](/filings/0000950170-23-065884.md) | [(5.91)](/filings/0000950170-24-131260.md) | [(6.38)](/filings/0001193125-25-288121.md) | [(5.48)](/filings/0001193125-25-288121.md) | [(3.84)](/filings/0001193125-25-288121.md) | | Free cash flow | $m | [(70.7)](/filings/0000950170-23-065884.md) | [(86.9)](/filings/0000950170-24-131260.md) | [(112)](/filings/0001193125-25-288121.md) | [(96.7)](/filings/0001193125-25-288121.md) | [(32.2)](/filings/0001193125-25-288121.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/enta/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $53.3m | 3,654,920 | | Not compared | | [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $47.7m | 3,784,055 | | Not compared | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $47.3m | 3,244,448 | | Added +140,680 | | [FARALLON CAPITAL MANAGEMENT, L.L.C.](/funds/909661.md) | 2026-06-30 | $35.3m | 2,418,202 | | Reduced −453,660 | | [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $21.1m | 1,444,167 | | Reduced −512,700 | | [ADAR1 Capital Management, LLC](/funds/1940272.md) | 2026-06-30 | $19.6m | 1,344,510 | | Added +1,293,153 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $17.7m | 1,211,769 | | Added +33,720 | | [Spruce Street Capital LP](/funds/2050194.md) | 2026-06-30 | $15.9m | 1,088,731 | | Added +156,133 | | [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $14.7m | 1,011,494 | | Added +62,590 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $11.3m | 776,634 | | Added +51,573 | ## Recent filings [All 830 filings](/companies/enta/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-29 | 16:05 ET | [8-K](/filings/0001193125-26-437774.md) | 8.01 Other events | 0001193125-26-437774 | | 2026-10-28 | 07:14 ET | [8-K](/filings/0001193125-26-435092.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-435092 | | 2026-08-12 | 07:00 ET | [10-Q](/filings/0001193125-26-345719.md) | Quarterly report, period 2026-06-30 | 0001193125-26-345719 | | 2026-08-10 | 16:05 ET | [8-K](/filings/0001193125-26-342336.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-342336 | | 2026-07-02 | 16:56 ET | [8-K](/filings/0001193125-26-294837.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-294837 | | 2026-06-23 | 17:28 ET | [8-K](/filings/0001193125-26-279803.md) | 8.01 Other events | 0001193125-26-279803 | | 2026-06-18 | 07:12 ET | [8-K](/filings/0001193125-26-274950.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-274950 | | 2026-05-13 | 07:00 ET | [10-Q](/filings/0001193125-26-220572.md) | Quarterly report, period 2026-03-31 | 0001193125-26-220572 | | 2026-05-11 | 16:05 ET | [8-K](/filings/0001193125-26-216735.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-216735 | | 2026-03-26 | 08:00 ET | [8-K](/filings/0001193125-26-125113.md) | 8.01 Other events | 0001193125-26-125113 | ## Latest annual report [Form 10-K for the fiscal year ended Sep 30, 2025](/filings/0001193125-25-288121.md), filed Nov 19, 2025. ## Forecast league Q4 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/543ca7d2-d162-4642-8ace-937fad87cab1) ## About the filer - CIK: 1177648 - Tickers: ENTA - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: not reported - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 16:06 ET. No prices; not investment advice.